FIELD: biotechnology.
SUBSTANCE: anti-CD137 antigen-binding molecules and a method for production thereof are disclosed. Also disclosed is an isolated nucleic acid coding an anti-CD137 antigen-binding molecule, an expression vector into which a nucleic acid is introduced and a host cell to produce an anti-CD137 antigen-binding molecule.
EFFECT: invention is used to produce anti-CD137 antigen-binding molecules, which have the effect of activating immunocytes, cytotoxic activity or anticancer activity, and at the same time have reduced effect on non-tumour tissues, such as normal tissues, and cause fewer side effects.
8 cl, 72 tbl, 91 dwg, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
